0000000000276299

AUTHOR

Antje Lebrecht

showing 19 related works from this author

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

2012

Noninvasive biomarkers are urgently needed for early detection of breast cancer since the risk of recurrence, morbidity and mortality are closely related to disease stage at the time of primary surgery. In the past decade, many proteomics-based approaches were developed that utilize the protein profiling of human body fluids or identification of putative biomarkers to obtain more knowledge on the effects of cancer emergence and progression. Herein, we report on an analysis of proteins in the tear fluid from breast carcinoma patients and healthy women using a de novo proteomic approach and 25 mixed samples from each group. This study included 25 patients with primary invasive breast carcinom…

AdultProteomicsCancer ResearchProteomediagnosisPopulationBreast NeoplasmsBiologyBioinformaticsProteomicsbreast cancerBreast cancerBiomarkers TumormedicineHumansEye ProteinseducationAgedAged 80 and overeducation.field_of_studyOncogeneCase-control studyCancerArticlesGeneral MedicineMiddle Agedmedicine.diseaseOncologyCase-Control StudiesSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationProteomebiomarkerElectrophoresis Polyacrylamide GelFemaleBreast carcinomatear fluidsOncology Reports
researchProduct

Immunoglobulin Kappa C Has Independent Prognostic Significance in Node-Negative Breast Cancer.

2009

Abstract Background: Utilizing microarray based gene-expression analysis of fresh-frozen tissue we could recently demonstrate the prognostic impact of a B cell metagene in node-negative breast cancer (Cancer Res 68: 5405-5413, 2008). In the present study we investigated the prognostic significance of immunoglobulin kappa c (IGKC) in formalin-fixed paraffin embedded (FFPE) breast cancer specimens of 363 node-negative breast cancer patients which were not treated in the adjuvant setting.Methods: RT-PCR was used to analyze mRNA expression of IGKC in FFPE tissue of 363 patients with node-negative breast cancer. Additionally to IGKC we examined the prognostic impact of age, histological grade, t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyMicroarraybusiness.industrymedicine.medical_treatmentEstrogen receptorCancermedicine.diseaseBreast cancermedicine.anatomical_structureOncologyInternal medicineProgesterone receptormedicinebusinessAdjuvantB cellCancer Research
researchProduct

Prognostic Influence of Pre-Operative C-Reactive Protein in Node-Negative Breast Cancer Patients

2014

The importance of inflammation is increasingly noticed in cancer. The aim of this study was to analyze the prognostic influence of pre-operative serum C-reactive protein (CRP) in a cohort of 148 lymph node-negative breast cancer patients. The prognostic significance of CRP level for disease-free survival (DFS), metastasis-free survival (MFS) and overall survival (OS) was evaluated using univariate and multivariate Cox regression, also including information on age at diagnosis, tumor size, tumor grade, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) status, proliferation index (Ki67) and molecular subtype, as well as an assessment of the…

PathologyProliferation indexReceptor ErbB-2lcsh:MedicineEstrogen receptorGastroenterologyMetastasisCohort StudiesBasic Cancer ResearchBreast TumorsMedicine and Health SciencesMedicineNeoplasm Metastasislcsh:ScienceImmune ResponseAged 80 and overUnivariate analysisMultidisciplinarybiologyCancer Risk FactorsHazard ratioObstetrics and GynecologyMiddle AgedPrognosisGene Expression Regulation NeoplasticC-Reactive ProteinOncologyReceptors EstrogenFemaleReceptors ProgesteroneResearch ArticleCancer Predisposing Conditions and SyndromesAdultmedicine.medical_specialtyImmunologyBreast NeoplasmsDisease-Free SurvivalBreast cancerInternal medicineBreast CancerHumansImmune EvasionAgedCell ProliferationProportional Hazards ModelsInflammationGenome Humanbusiness.industryProportional hazards modelGene Expression Profilinglcsh:RC-reactive proteinImmunityBiology and Life SciencesCancers and NeoplasmsCancermedicine.diseaseKi-67 Antigenbiology.proteinWomen's Healthlcsh:QClinical ImmunologyLymph NodesbusinessPLoS ONE
researchProduct

Transforming Growth Factor Beta 1 Serum Levels in Patients with Preinvasive and Invasive Lesions of the Breast

2004

Transforming growth factor beta (TGF-beta)1 is thought to be involved in breast carcinogenesis. TGF-beta1 acts in an antiproliferative manner in the early stages of breast carcinogenesis, but promotes tumor progression and metastases in the advanced stages of the disease. No data have been published on serum TGF-beta1 in breast cancer. We investigated TGF-beta1 serum levels in patients with breast cancer (n=135), ductal carcinoma in situ (DCIS) I to III (n=67) or fibroadenoma (n=35), and in healthy women (n=40) to determine its value as a differentiation marker between malignant, pre-invasive and benign diseases and as a predictive marker for metastatic spread. Median (range) TGF-beta1 seru…

AdultOncology0301 basic medicinemedicine.medical_specialtyPathologyCancer ResearchMammary glandClinical BiochemistryCA 15-3Breast NeoplasmsPathology and Forensic MedicineTransforming Growth Factor beta103 medical and health sciencesBreast cancer0302 clinical medicineTransforming Growth Factor betaInternal medicinemedicineHumansNeoplasm Invasivenessskin and connective tissue diseasesEstrogen Receptor StatusAgedNeoplasm StagingAged 80 and overPredictive markerbusiness.industryMiddle AgedDuctal carcinomamedicine.diseaseFibroadenomamedicine.anatomical_structure030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisbusinessThe International Journal of Biological Markers
researchProduct

Monocyte Chemoattractant Protein-1 Serum Levels in Patients with Breast Cancer

2003

The chemokine monocyte chemoattractant protein (MCP)-1 is thought to be involved in breast carcinogenesis. We evaluated MCP-1 serum levels in patients with breast cancer (n = 135), ductal carcinoma in situ (DCIS) I-III (n = 30), benign breast lesions (n = 143) and in healthy women (n = 27). We determined the value of MCP-1 serum levels as a differentiation marker between malignant, preinvasive and benign breast diseases and as a predictive marker for the biological phenotype of breast carcinoma. Median (range) MCP-1 serum levels in patients with breast cancer, DCIS I-III, benign breast lesions and healthy women were 200 (57-692) pg/ml, 194 (58-525) pg/ml, 174 (39-529) pg/ml and 175 (67-425)…

AdultOncologymedicine.medical_specialtyCA 15-3Breast NeoplasmsBreast DiseasesBreast cancerReference ValuesInternal medicineBiomarkers TumormedicineCarcinomaHumansNeoplasm Invasivenessskin and connective tissue diseasesLymph nodeChemokine CCL2AgedRetrospective StudiesPredictive markerbusiness.industryCase-control studyGeneral MedicineMiddle AgedDuctal carcinomamedicine.diseaseCarcinoma Intraductal NoninfiltratingCell Transformation NeoplasticPhenotypemedicine.anatomical_structureCase-Control StudiesLymphatic MetastasisFemaleBreast carcinomabusinessTumor Biology
researchProduct

Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.

2011

Non-invasive biomarkers for early breast cancer detection are urgently needed, as the risk of recurrent morbidity and mortality is closely related to the stage of the disease at the time of primary surgery. Currently, there are no established clinical biomarkers for breast cancer. Evaluation of protein expression patterns in body fluids using proteomic technologies can be used to discover new biomarkers for the detection of breast cancer. The aim of this study was to identify a biomarker signature identifying primary non-metastatic breast cancer and healthy controls. We screened 91 serum samples including 45 breast cancer patients and 46 healthy women using a proteomic approach. We found 14…

OncologyAdultProteomicsCancer Researchmedicine.medical_specialtyEarly breast cancer detectionProteomeBreast NeoplasmsDiseaseBiologyBioinformaticsBreast cancerInternal medicinemedicineBiomarkers TumorHumansskin and connective tissue diseasesEarly Detection of CancerAgedAged 80 and overOncogeneGeneral MedicineMiddle Agedmedicine.diseaseMolecular medicineOncologySerum proteomeSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBiomarker (medicine)FemalePrimary breast cancerOncology reports
researchProduct

Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes

2020

Interferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype-specific prognostic significance of interferon-&gamma

OncologyMicroarrayReceptor ErbB-2animal diseasesKaplan-Meier Estimatelcsh:ChemistryMedicinelcsh:QH301-705.5Spectroscopymolecular subtypesHazard ratioGeneral MedicineinterferonMiddle AgedAcquired immune systemProgression-Free SurvivalComputer Science ApplicationsGene Expression Regulation NeoplasticReceptors EstrogenCohortFemaleReceptors ProgesteroneSignal Transductionmedicine.medical_specialtyBreast Neoplasmschemical and pharmacologic phenomenaDisease-Free SurvivalArticleCatalysisInorganic ChemistryInterferon-gammaBreast cancerImmune systembreast cancerInternal medicineBiomarkers TumorHumansPhysical and Theoretical ChemistryMolecular BiologyAgedNeoplasm Stagingbusiness.industryProportional hazards modelOrganic Chemistrybreast cancer ; prognosis ; interferon ; molecular subtypesbiochemical phenomena metabolism and nutritionGene signaturemedicine.diseaselcsh:Biology (General)lcsh:QD1-999bacteriaprognosisbusinessInternational Journal of Molecular Sciences
researchProduct

Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

2011

Abstract Background In recent years, surgeons have utilized Harmonic instruments to perform breast cancer resection. Retrospective and prospective studies have demonstrated that the use of this surgical device for mastectomy and axillary dissection can reduce perioperative blood loss, seroma formation, and duration and total amount of drainage. No study has analyzed the feasibility of Harmonic instruments in breast-conserving surgery. We conducted a prospective, randomized clinical trial comparing Harmonic instrument and conventional surgery in the performance of breast-conserving surgery and axillary procedures to determine differences in surgical procedures, postoperative outcome, and com…

Adultmedicine.medical_specialtymedicine.medical_treatmentUltrasonic TherapyBreast NeoplasmsMastectomy SegmentalRisk AssessmentStatistics Nonparametriclaw.inventionBreast cancerPostoperative ComplicationsRandomized controlled triallawGermanymedicineBreast-conserving surgeryHumansNeoplasm InvasivenessProspective StudiesProspective cohort studyAgedNeoplasm StagingPostoperative CareAcademic Medical CentersChi-Square Distributionbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseSurgical InstrumentsSurvival AnalysisSurgeryLogistic ModelsSeromaTreatment OutcomeOncologySeromaMultivariate AnalysisSurgeryFemaleNeoplasm Recurrence LocalComplicationbusinessChi-squared distributionMastectomyFollow-Up StudiesEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Prognostic significance of the chemokine CXCL13 in node-negative breast cancer

2013

615 Background: The chemokine CXCL13 is chemotactic for B cells. We examined the prognostic significance of CXCL13 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for CXCL13 (205242_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of CXCL13 on metastasis-free survival (MFS) was examined in the whole cohort and in different molecular subtypes (ER+/HER2-, ER-/HER2-, HER2+). Independent prognostic relevance was a…

OncologyCancer Researchmedicine.medical_specialtyChemokineMicroarraybiologybusiness.industryMrna expressionObstetrics and GynecologyChemotaxismedicine.diseaseNode negativeBreast cancerOncologyInternal medicineMaternity and MidwiferyImmunologyCancer researchbiology.proteinMedicineCXCL13businessGeburtshilfe und Frauenheilkunde
researchProduct

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St G…

2009

Background: Defining risk categories in breast cancer is of considerable clinical significance. We have developed a novel risk classification algorithm and compared its prognostic utility to the Web-based tool Adjuvant! and to the St Gallen risk classification. Patients and methods: After a median follow-up of 10 years, we retrospectively analyzed 410 consecutive node-negative breast cancer patients who had not received adjuvant systemic therapy. High risk was defined by any of the following criteria: (i) age 2 cm. All patients were also characterized using Adjuvant! and the St Gallen 2007 risk categories. We analyzed disease-free survival (DFS) and overall survival (OS). Results: The Node-…

AdultTime FactorsBreast NeoplasmsKaplan-Meier EstimateRisk AssessmentSensitivity and SpecificityDisease-Free SurvivalBreast cancerBreast cancer 3Predictive Value of TestsMedicineHumansLongitudinal StudiesProspective StudiesRisk factorAgedNeoplasm StagingRetrospective StudiesAged 80 and overNeovascularization Pathologicbusiness.industryHazard ratioCancerRetrospective cohort studyHematologyGenes erbB-2Middle Agedmedicine.diseasePrognosisImmunohistochemistrySurvival AnalysisTreatment OutcomeOncologyAdult; Aged; Aged 80 and over; Algorithms; Breast Neoplasms/genetics; Breast Neoplasms/pathology; Breast Neoplasms/radiotherapy; Breast Neoplasms/surgery; Disease-Free Survival; Female; Follow-Up Studies; Genes erbB-2; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neovascularization Pathologic; Predictive Value of Tests; Prognosis; Prospective Studies; Receptors Progesterone/analysis; Regression Analysis; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment OutcomeMultivariate AnalysisRegression AnalysisFemaleBreast diseasebusinessRisk assessmentReceptors ProgesteroneAlgorithmAlgorithmsFollow-Up Studies
researchProduct

Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer: results of an explorative, retrospective study.

2013

The identification of prognostic markers has clinical implications in epithelial ovarian carcinoma (EOC). Here, we studied markers for proliferation (Ki-67), endocrine regulation [progesterone receptor (PR), estrogen receptor (ER)], and invasion [urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1)]. All patients with available follow-up information and EOC tissue, who were treated at our institution between 1997 and 2004, were enrolled in the present study. Expression of Ki-67, PR and ER was determined by immunohistochemical analyses. uPA and PAI-1 antigen levels were determined using enzyme‑linked immunosorbent assays. One hundred and eight patients enter…

OncologyCancer Researchmedicine.medical_specialtyCarcinoma Ovarian EpithelialDisease-Free SurvivalCohort StudiesInternal medicineProgesterone receptorPlasminogen Activator Inhibitor 1medicineBiomarkers TumorHumansNeoplasms Glandular and EpithelialProspective cohort studyCell ProliferationRetrospective StudiesUrokinaseOvarian Neoplasmsbiologybusiness.industryProportional hazards modelHazard ratioCancerGeneral MedicineMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorTumor BurdenKi-67 AntigenOncologyReceptors EstrogenKi-67biology.proteinFemalebusinessOvarian cancerReceptors Progesteronemedicine.drugOncology reports
researchProduct

Prognostic significance of Focal Adhesion Kinase (FAK) in node-negative breast cancer.

2015

552 Background: Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase playing an important role as a key mediator for signal transduction. We examined the subtype specific prognostic signifi...

CYTOPLASMIC TYROSINE KINASECancer ResearchPathologymedicine.medical_specialtybusiness.industrymedicine.diseaseNode negativeFocal adhesionMediatorBreast cancerOncologymedicineCancer researchSignal transductionbusinessJournal of Clinical Oncology
researchProduct

Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.

2004

BACKGROUND Genes encoding enzymes involved in estrogen metabolism are held to be candidate genes for associations with breast disease. In these candidate genes, no critical combination of single-nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date. METHODS In a large case–control study, the authors investigated 10 estrogen-metabolizing SNPs in 396 patients with breast carcinoma, 154 patients with fibroadenoma, and 1936 healthy control patients without breast carcinoma in their personal history. The following 10 SNPs were analyzed using sequencing-on-chip technology via a solid-phase polymerase chain reaction assay performed on oligonucleotide microar…

OncologyRiskCancer Researchmedicine.medical_specialtyCandidate geneSingle-nucleotide polymorphismBreast NeoplasmsPolymorphism Single NucleotideWhite PeopleGene FrequencyInternal medicineGenotypeCarcinomaCytochrome P-450 CYP1A1MedicineHumansGenetic Predisposition to Diseasebusiness.industryCarcinomaCancerSteroid 17-alpha-HydroxylaseEstrogensMiddle Agedmedicine.diseaseFibroadenomaEndocrinologyOncologyFibroadenomaCase-Control StudiesFemaleBreast diseasebusinessBreast carcinomaCancer
researchProduct

c-met is overexpressed in type I ovarian cancer: Results of an investigative analysis in a cohort of consecutive ovarian cancer patients

2016

The tyrosine kinase c-met alters signaling cascades such as the BRAF-MAPK and PI3K-PKB pathways. These alterations are involved in the carcinogenesis of type I but not type II ovarian cancer (OC). Therefore, the present study investigated the patterns of c-met expression in a cohort of consecutive patients with OC. c-met expression was determined by immunohistochemical analysis. Differences in c-met overexpression among subgroups of established clinicopathological features, including age, histological subtype, tumor stage, histological grading, post-operative tumor burden and completeness of chemotherapy, were determined by χ2 test. Cox regression analyses were performed to determine the pr…

0301 basic medicineOncologyCancer ResearchPathologymedicine.medical_specialtyC-Metmedicine.medical_treatmentBiologymedicine.disease_cause03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineChemotherapyOncogeneProportional hazards modelArticlesmedicine.diseaseMolecular medicine030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisCohortCarcinogenesisOvarian cancerOncology Letters
researchProduct

Immunoglobulin Kappa C Predicts Overall Survival in Node-Negative Breast Cancer

2012

Background: Biomarkers of the immune system are currently not used as prognostic factors in breast cancer. We analyzedthe association of the B cell/plasma cell marker immunoglobulin kappa C (IGKC) and survival of untreated node-negative breast cancer patients.Material and Methods: IGKC expression was evaluated by immunostaining in a cohort of 335 node-negative breast cancer patients with a median follow-up of 152 months. The prognostic significance of IGKC for disease-free survival (DFS) and breast cancer-specific overall survival (OS) was evaluated with Kaplan-Meier survival analysis as well as univariate and multivariate Cox analysis adjusted for age at diagnosis, pT stage, histological g…

OncologyPathologyB CellsEpidemiology610 MedizinEstrogen receptorlcsh:MedicineMetastasis610 Medical sciencesBasic Cancer ResearchPathologyStage (cooking)lcsh:ScienceUnivariate analysisMultidisciplinaryHazard ratioObstetrics and GynecologyMiddle AgedImmunohistochemistryOncologyMedicineFemaleResearch Articlemedicine.medical_specialtyImmune CellsImmunoglobulinsBreast NeoplasmsDisease-Free SurvivalImmunoglobulin kappa-ChainsBreast cancerDiagnostic MedicineInternal medicineProgesterone receptorBreast CancermedicineHumansAntibody-Producing CellsSurvival analysisImmune Evasionbusiness.industrylcsh:RImmunitymedicine.diseaseConfidence intervalBiomarker EpidemiologyHumoral Immunitylcsh:QClinical ImmunologybusinessBiomarkersGeneral Pathology
researchProduct

Antibody microarray analysis of the serum proteome in primary breast cancer patients

2011

Noninvasive biomarkers are urgently needed for detecting breast cancer as early as possible since the risk of recurrence, morbidity, and mortality is closely related to disease stage at the time of primary surgery. There are currently no such biomarkers in clinical use as a diagnostic tool. Proteomic analysis of protein expression patterns in body fluids has potential for use in identifying biomarkers of breast cancer. The aim of this study was to compare protein expression levels in the sera of primary breast cancer patients and healthy controls. An antibody microarray tool with 23 antibodies immobilized on nitrocellulose slides was used to determine the levels of acute phase proteins, int…

AdultOncologyCancer Researchmedicine.medical_specialtyProteomeAntibody microarrayProtein Array AnalysisBreast NeoplasmsDiseaseBreast cancerInternal medicineBiomarkers TumorHumansMedicineStage (cooking)AgedAged 80 and overImmunoassayPharmacologybiologybusiness.industryAcute-phase proteinInterleukinMiddle Agedmedicine.diseaseOncologyCase-Control StudiesImmunologybiology.proteinMolecular MedicineFemaleNeoplasm GradingAntibodybusinessPrimary breast cancerCancer Biology & Therapy
researchProduct

Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer

2008

Abstract Purpose: Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention not only as a prognostic factor in breast cancer but also as a potential target for immunotherapy. We examined Ep-CAM expression in 402 consecutive node-negative breast cancer patients with long-term follow-up not treated in the adjuvant setting. Experimental Design: Ep-CAM expression was evaluated by immunostaining. Its prognostic effect was estimated relative to overexpression/amplification of HER-2, histologic grade, tumor size, age, and hormone receptor expression. Results: Ep-CAM status was positive in 106 (26.4%) patients. In multivariate analysis, Ep-CAM status was associated with disea…

AdultOncologyCancer ResearchPathologymedicine.medical_specialtyNeoplasms Hormone-DependentEstrogen receptorBreast Neoplasmschemistry.chemical_compoundDrug Delivery SystemsBreast cancerAntigens NeoplasmInternal medicineProgesterone receptorBiomarkers TumormedicineHumansAgedAged 80 and overbusiness.industryHazard ratioCancerEpithelial cell adhesion moleculeMiddle AgedEpithelial Cell Adhesion MoleculePrognosismedicine.diseaseOncologychemistryHormone receptorLymphatic MetastasisFemaleBreast diseasebusinessCell Adhesion MoleculesClinical Cancer Research
researchProduct

Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.

2014

620 Background: The transcription factor IRF4 (interferon regulating factor 4) regulates immunoglobulin class switch recombination as well as plasma cell differentiation. We examined the prognostic significance of IRF4 mRNA expression in node-negative breast cancer. Methods: Microarray based gene-expression data for IRF4 (204562_at) were analysed in four previously published cohorts (Mainz, Rotterdam, Transbig, Yu) of node-negative breast cancer patients not treated with adjuvant therapy (n=824). A meta-analysis of previously published cohorts was performed using a random effects model. Prognostic significance of IRF4 on metastasis-free survival (MFS) was examined in the whole cohort and in…

Cancer ResearchMicroarraybusiness.industrymedicine.diseaseBreast cancerOncologyInterferonPlasma cell differentiationImmunologyCancer researchmedicineAdjuvant therapyAurora Kinase Askin and connective tissue diseasesbusinessTranscription factorIRF4medicine.drugJournal of Clinical Oncology
researchProduct

Quality of life and adjuvant tamoxifen treatment in breast cancer patients

2009

About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patie…

AdultOncologymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBreast NeoplasmsBreast cancerQuality of lifeSurveys and QuestionnairesInternal medicineBody ImagemedicineHumansskin and connective tissue diseasesAgedAged 80 and overChemotherapyAdjuvant tamoxifenbusiness.industryMiddle Agedmedicine.diseaseMental healthTamoxifenOncologyChemotherapy AdjuvantQuality of LifeHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugEuropean Journal of Cancer Care
researchProduct